GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MyMD Pharmaceuticals Inc (NAS:MYMD) » Definitions » EV-to-FCF

MyMD Pharmaceuticals (MyMD Pharmaceuticals) EV-to-FCF : -0.27 (As of May. 22, 2024)


View and export this data going back to 2021. Start your Free Trial

What is MyMD Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, MyMD Pharmaceuticals's Enterprise Value is $2.96 Mil. MyMD Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-10.92 Mil. Therefore, MyMD Pharmaceuticals's EV-to-FCF for today is -0.27.

The historical rank and industry rank for MyMD Pharmaceuticals's EV-to-FCF or its related term are showing as below:

MYMD' s EV-to-FCF Range Over the Past 10 Years
Min: -41.26   Med: 0   Max: 0.24
Current: -0.33

During the past 4 years, the highest EV-to-FCF of MyMD Pharmaceuticals was 0.24. The lowest was -41.26. And the median was 0.00.

MYMD's EV-to-FCF is ranked worse than
100% of 376 companies
in the Biotechnology industry
Industry Median: 9.49 vs MYMD: -0.33

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), MyMD Pharmaceuticals's stock price is $2.03. MyMD Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.570. Therefore, MyMD Pharmaceuticals's PE Ratio for today is At Loss.


MyMD Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for MyMD Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MyMD Pharmaceuticals EV-to-FCF Chart

MyMD Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- -11.12 -3.33 -0.84

MyMD Pharmaceuticals Quarterly Data
Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.79 -3.63 -1.52 -0.84 -0.33

Competitive Comparison of MyMD Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, MyMD Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MyMD Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MyMD Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where MyMD Pharmaceuticals's EV-to-FCF falls into.



MyMD Pharmaceuticals EV-to-FCF Calculation

MyMD Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2.955/-10.921
=-0.27

MyMD Pharmaceuticals's current Enterprise Value is $2.96 Mil.
MyMD Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MyMD Pharmaceuticals  (NAS:MYMD) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

MyMD Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.03/-9.570
=At Loss

MyMD Pharmaceuticals's share price for today is $2.03.
MyMD Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.570.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


MyMD Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of MyMD Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


MyMD Pharmaceuticals (MyMD Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205
MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-1R is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and a monoamine oxidase enzyme type B.
Executives
Paul Rivard officer: EVP of Operations, GC C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Caroline C Williams 10 percent owner 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Adam Kaplin officer: Chief Scientific Officer C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Jude Uzonwanne director C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Craig Eagle director POST OFFICE BOX 4590, NEW YORK NY 10163
Chapman Christopher C Jr director, officer: President, Chief Med. Officer C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814
Ian Rhodes officer: Interim CFO 1375 KINGS HIGHWAY EAST, FAIRFIELD CT 06824
Stuart M Benson officer: Chief Financial Officer EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118
Hudson Bay Capital Management Lp 10 percent owner 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Sander Gerber 10 percent owner C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Robert C Schroeder director 37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724
Howard Yeaton officer: CEO, CFO 79 LLOYD ROAD, HOHOKUS NJ 07423
Tarbox Richard C Iii director AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Christopher C Schreiber director AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086

MyMD Pharmaceuticals (MyMD Pharmaceuticals) Headlines

From GuruFocus